NHLBI San Diego Innovation Conference
A NHLBI Conference Powered by Prescience International
Tuesday June 11, 2013 | Janssen Research & Development
This conference brings together small businesses, angel investors, venture capitalists, strategic partners, and business leaders from the biotech and pharmaceutical industries. It will feature presentations by top NHLBI SBIR- funded companies with innovative technologies on the brink of commercialization, an expert panel of investors, and opportunities for partnering and networking. Information about the NHLBI Office of Translational Alliances and Coordination, changes in the SBIR/STTR program re-authorization, and other funding opportunities and resources will be presented. NHLBI staff will be available to provide advice to applicants and awardees.
The NHLBI provides global leadership for research, training, and education to promote the prevention and treatment of heart, lung, blood, and sleep diseases and disorders and to enhance the health of all individuals so that they can live longer and more fulfilling lives.
The investor perspectives panel will feature a distinguished panel of experts from the investor community.
10:30 - 11:00 a.m. | Registration
11:00 - 11:15 a.m. | Welcome Remarks
11:15 - 11:30 a.m. | NHLBI Presentation
11:30 - 11:45 a.m. | Capricor, Inc.
11:45 - 12:00 p.m. | Fallbrook Engineering
12:00 - 12:15 p.m. | KAER Biotherapeutics
12:15 - 12:45 p.m. | Lunch
12:45 - 1:00 p.m. | Targeson, Inc.
1:00 - 1:15 p.m. | Vala Sciences
1:15 - 1:30 p.m. | Vascular BioSciences
1:30 - 2:30 p.m. | Investor Perspectives Panel
2:30 - 2:45 p.m. | NHLBI Presentation
2:45 - 3:00 p.m. | Closing Remarks
3:00 - 5:00 p.m. | Networking Reception
America Stem Cell (ASC)
BioData Innovation Systems
Stephen Flaim, Special Advisor, NHLBI & Member, Tech Coast Angels SD (moderator)
Flaim holds a doctorate in Human Physiology and Pharmacology from the UC Davis. He held faculty positions in Medicine and Physiology at the Pennsylvania State University College of Medicine and senior management roles at the J&J Pharmaceutical Research Institute, the Squibb Institute for Medical Research, Alliance Pharmaceutical Corporation, Trega Biosciences and Galileo Pharmaceuticals. Flaim is Founder & President of Flaim Partners Consulting, a Fellow of the American College of Cardiology, the AHA, the American College of Clinical Pharmacology, and the Royal Society of Medicine. He is a board member of Pivotal Biosciences and AnaBios Corporation, Chairman of the Board for Leading Biosciences, on the Editorial Board of the Journal of Pharmacology and Experimental Therapeutics, a Technology and Business advisor to the William J. von Liebig Center for Entrepreneurism and Technology Advancement at UCSD, Chairman of TCA and Chairman of the John G. Watson Foundation. Flaim is Cofounder & CEO of CardioCreate and Chairman & CEO of OncoFluor. Flaim is Special Advisor to the Office of Translational Alliances and Coordination in the Division of Extramural Research Activities, NHBLI of the NIH.
Beth Hill, Platform Innovation Lead, Johnson & Johnson Innovation Center
Beth Hill is currently Platform Innovation Lead for the J&J Innovation Center in California where she builds collaborative partnerships with life science technology innovators to accelerate the development of transformational medicines. During her prior 10 years with J&J Beth led cross-disciplinary teams at ALZA, Centocor, and Janssen, to create and apply technologies that overcome technical and business barriers and address unmet patient needs. From 2000-2002, Beth was Director of Cellular Immunology at Corixa leading R&D efforts to develop therapeutics for cancer and autoimmune disease. From 1992 to 2000 Beth held a series of R&D leadership roles in stem, somatic cell and gene therapies at Systemix /Novartis eventually becoming Deputy Head of Research. Beth began her industrial career developing antibody-based diagnostics at Syva Co. Beth received her BA in Medical Technology from Augustana College and her Ph.D in Microbiology from Columbia University, College of Physicians and Surgeons. Her post-doctoral fellowship at Stanford University was in the Dept. of Cell and Structural Biology.
Allan May, Founder & Chairman, Life Science Angels
Allan is a founder of Life Science Angels (www.lifescienceangels.com ), the largest angel organization in the U.S. focused solely on early stage medical device and life science start-ups, and comprised solely of high net worth individuals from the medical device or biotech fields. LSA has invested over $35M in 40 startups and achieved 7 positive exits to date. In 2011, Allan launched the Life Science Angel Network, a consortium of 15 angel groups throughout the United States, to focus on increasing the syndication and capitalization of highly vetted healthcare startups. Since 1995, Allan has been founder, Chairman, CEO, or investor in over 50 medtech, biotech, and diagnostic startups. He has led the business section of Singularity University’s FutureMed program, and speaks frequently at universities, conferences and government programs on trends and developments affecting early stage biotech and medtech investing. Allan is also a member of the boards of the Open Medicine Institute and Vascular Cures, and a member of the advisory board of the UCSF Entrepreneurship Center.
Peter McWilliams, Managing Director, Sanderling Ventures
Peter McWilliams, Ph.D. is a Managing Director with Sanderling Ventures and has more than 15 years of experience in biomedical research and management. He works actively with Sanderling portfolio companies in the role of Chairman, Director, CEO and member of the management team. Portfolio companies include Actimis Pharmaceuticals (sold to Boehringer Ingelheim), Artielle Immunotherapeutics, Axikin Pharmaceuticals and Calcimedica. Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development. He was the Commercial Team Leader for Avastin, a first-in-class anti-angiogenic therapy for cancer. Prior to that he was an Associate with Booz Allen & Hamilton, where he focused on consulting projects for major multi-national lifescience companies. Prior to that he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bioinformatics, where he helped to set up and establish their US operations prior to their successful IPO on the London Stock Exchange and ultimate acquisition by Accelrys (NASDAQ: ACCL).
FREE (space is limited)
@NHLBI_SBIR | #NHLBIshowcase
Madelaine Holden | email@example.com
When & Where
The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.
The NHLBI stimulates basic discoveries about the causes of disease, enables the translation of basic discoveries into clinical practice, fosters training and mentoring of emerging scientists and physicians, and communicates research advances to the public. It creates and supports a robust, collaborative research infrastructure in partnership with private and public organizations, including academic institutions, industry, and other government agencies. The Institute collaborates with patients, families, health care professionals, scientists, professional societies, patient advocacy groups, community organizations, and the media to promote the application of research results and leverage resources to address public health needs. The NHLBI also collaborates with international organizations to help reduce the burden of heart, lung, and blood diseases worldwide.